NCT06751394View on ClinicalTrials.gov

Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Recurrent Rectal Cancer
Interventions
DRUG

PD-1 antibody (Toripalimab)

PD-1 antibody: (Toripalimab): 240mg q3w

DRUG

Capecitabine

Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy

DRUG

Oxaliplatin

130 mg/m² q3w

DRUG

Irinotecan

200 mg/m² q3w

RADIATION

Radiation

45-50Gy/25Fx or 30Gy/15Fx

PROCEDURE

surgery

The type of surgery will depend on the site of recurrence and the involvement of adjacent structures, which will be determined by the surgeons.

Trial Locations (1)

510655

Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER